Human embryonic kidney 293 cells contain the E1 region E1-E3 regions, in an unpackagable form. Investigation of of adenovirus type 5, and thus sustain, through transcompthe reason for massive cell death after cotransfection led lementation, the production of recombinant E1-deleted us to determine that 293 cells express the FasL receptor, adenovirus vectors. During attempts to produce recombiFas-Apo1 (CD95), and respond with apoptosis to the nant adenovirus expressing the apoptosis-inducing molcross-linking of Fas-Apo1 with either IgM monoclonal antiecule Fas ligand (FasL) under the control of a very strong bodies or FasL. Therefore, we decided to generate adenotruncated major immediate-early human cytomegalovirus viral vectors expressing FasL under the control of tissue-(MIEhCMV) promoter, we discovered that 293 cells were specific and/or -inducible promoter elements. Our findings not surviving the initial cotransfection with a shuttle plasmid can explain difficulties several groups have had in generatencoding the mouse FasL; and pJM17, a plasmid containing recombinant adenoviral vectors expressing FasL using ing the genome of adenovirus type 5 with deletions in the 293 cells, as well as the lower titres reported.
Fas-ligand (FasL) is a cell surface molecule, member of the tumour necrosis factor family, that triggers apoptosis in cells expressing its receptor, Fas/Apo-1 (CD95). 1 The pattern of expression of FasL and of Fas/Apo-1 throughout the body, and the functional significance of Fas-FasL interactions are only now being characterised. Recent data point to two main functions of FasL, namely, to maintain immune homeostasis, and to contribute to the molecular basis of immune-privileged sites. 2 Interactions between FasL and Fas/Apo-1 are involved in the induction of peripheral tolerance by causing apoptosis in selfreactive T lymphocytes, the down-regulation of lymphoid expansion via lymphocyte-lymphocyte interactions, and the reduction of excess active lymphocytes remaining following an immune response. 3 Bellgrau et al 4 have recently demonstrated that endogenous FasL expressed by testis' Sertoli cells abolishes the rejection of testicular allografts, probably by inducing apoptosis of Fas/Apo-1 expressing reactive T lymphocytes. The observation that endogenous FasL appeared to play a central role in maintaining the immune privilege of the anterior chamber of the eye and allowed the survival of testis' allografts, led to the proposal to use FasL to protect allografted cells from rejection. 4, 5 Lau et al 6 reported the successful use of FasL-transfected syngeneic myoblasts to protect cotrans-planted pancreatic islet allografts from immune rejection. Colon carcinoma cells engineered to express FasL gave rise to markedly reduced allogeneic cytotoxic T cells and helper T cells, as well as restricted alloantibody response when compared to control cells. 7 Similarly, chromaffin cell xenografts to the brain were 'shielded' by syngeneic Sertoli cells bearing endogenous FasL. 8 Data indicating a role for FasL in maintaining immune homeostasis, immune privilege and the capacity to 'shield' allo-and xenografts from immune rejection suggested it could also have a role in down-modulating the immune response to tumours. Consequently, expression of FasL was discovered in different types of human tumours (ie melanoma, hepatocellular carcinoma, colon, lung, etc), and it was suggested that its expression could contribute to the tumours' immune evasion. [9] [10] [11] [12] However, more recent data have challenged the immune privilege-conferring role of FasL by showing that transgenic FasL is not able to protect pancreatic islet allografts from immune rejection. Further data also show that in certain experimental situations FasL acts as a proinflammatory cytokine accelerating graft rejection, and inducing granulocytic infiltration. 13, 14 Thus, the activity of FasL is more complex than initially realized. It has now been shown that it can either contribute to the maintenance of immune privilege, cause apoptosis of Fas/Apo-1-expressing cells, or induce granulocytic infiltration of tissues. Which effect it displays in a given experimental situation would appear to depend on a wide variety of factors, including the type of tissue expressing FasL, the developmental timing of its expression, or the presence or absence of as yet unidentified contributing factors.
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The proteins constituting the adenovirus virion, the viral proteins still expressed from the adenovirus genome in first generation E1/E3-deleted recombinant adenoviral vectors (RAd), as well as those transgenic products encoded by them, are all capable of inducing an acute inflammatory response, which is followed by the development of an adaptive immune response. [15] [16] [17] The inflammatory and subsequent cellular immune responses lead to the eventual rejection of adenoviral vectorinfected cells, and constitute an impediment to long-term expression of transgenes using adenoviral vectors. [15] [16] [17] The capacity of FasL to reduce alloantibody responses and to induce apoptosis in natural killer cells and cytotoxic T lymphocytes bearing Fas/Apo1 led us to attempt the construction of recombinant adenoviruses expressing FasL to prolong transgene expression from adenoviral vectors. However, during cotransfections of 293 cells designed to produce recombinant adenoviral vectors, we found that the transfection of a plasmid encoding FasL under a potent constitutive promoter led to massive cell death of 293 cells and hampered the generation of recombinant adenoviruses. In the present report, we demonstrate that 293 cells express Fas/Apo-1 on their cell surface and can be induced to enter apoptosis either after cross-linking Fas/Apo-1 on the surface of 293 cells using anti-Fas/Apo-1 monoclonal antibodies, or following the transient transfection with two different plasmids encoding the mouse FasL molecule under the transcriptional control of a constitutive promoter. A comparable observation has been made recently in studies of the effect of FasL on pancreatic islet transplants, where it was reported that low levels of RAd-encoding FasL were harvested from 293 cells because the latter died upon scaling up production. 18 To determine the expression of Fas/Apo-1 on the surface of 293 cells, cells were immunostained with several monoclonal antibodies specific for human Fas/Apo-1 and were analysed by flow cytometry (monoclonal antibodies B.D29, B.E28, B.G27, B.G30, B.G34, B.K14, B.L25 were provided by J Wijdenes (Diadone, Besançon, France); monoclonal antibody CH11 was supplied by S Yonehara (Pharmaceutical Basic Research Laboratories JT, Yokohama, Japan); and monoclonal antibody 7C11 was provided by MJ Robertson (Harvard University, Boston, MA, USA); all these antibodies are specific for human Fas/Apo-1). As depicted in Figure 1 , the level of Fas/Apo-1 was high enough to be detected on the cell membrane of 95 to 99% of 293 cells.
To determine whether the Fas/Apo-1 was able to deliver an apoptotic signal to 293 cells, we incubated 293 cells with different concentrations of two different IgM mAbs recognizing human Fas/Apo-1 (mAbs CH11 and 7C11). It is known that receptor oligomerization is required for the generation of the apoptotic signal triggered by Fas/Apo-1, and that such oligomerization can be induced by polyvalent mAbs recognizing Fas/Apo-1 or by the natural ligand, FasL. 293 Cells incubated with irrelevant mouse IgM were used as control. The percentage of apoptotic cells was studied by flow cytometry 24 h following the addition of antibodies. Cells were fixed with 4% of paraformaldehyde, permeabilised with Triton X-100, washed with phosphate buffer solution (PBS), and incubated with propidium iodide to stain DNA, as was previously described by Nicoletti et al. 19 After such treatment, apoptotic cells appear as a broad hypoploid DNA peak, well separated from the normal diploid distribution of DNA within nonapoptotic cells. Figure 2 illustrates that 293 cells are prone to die by apoptosis triggered by the two IgM mAbs specific for Fas/Apo-1. The percentage of apoptotic 293 cells was dependent on the concentration of antibodies used, since it increased from 20 to 30% when antibody concentration was raised from 2 to 4 g/ml.
We next examined whether 293 cells were also prone to be killed by apoptosis induced by Fas-L, the natural ligand of Fas/Apo-1. 293 Cells were transiently transfected using the calcium phosphate method with 5 g of the BCMGS Neo expression plasmid (pBCMGS Neo) or with 5 g of the plasmid pAL119, both encoding for the C57BL/6 mouse FasL both under the control of different versions of the hCMV-IE promoter: pBCMGS Neo contains 745 bp of the hCMV-IE promoter/enhancer; and pAL119 encoded for a truncated MiEhCMV promoter containing only the sequence from −299 to +69 where the upstream enhancer sequences and the upstream modulator region have been removed. 6, 20, 21 Mouse FasL has been previously shown to bind to human Fas/Apo-1.
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Mouse FasL cDNA was subcloned from pBS(−)KS (Stratagene, La Jolla, CA, USA) into the XhoI and NotI sites of pBCMGS Neo, and into the BamHI sites of pAL119. 21, 23 As control, 293 cells mock-transfected or transfected with 5 g of empty pBCMGS Neo were included. As soon as 24 h after pBCMGS Neo-FasL or pAL119-FasL transfection, most 293 cells were detached from the flask showing typical morphological features of apoptosis (eg chromatin condensation and fragmentation of nucleus and cytoplasm) (Figure 3 ). According to the flow cytometric analysis, 69 ± 6% of cells were apoptotic
Figure 2 Analysis by flow cytometry of apoptosis of 293 cells triggered by mAb specific for human Fas/Apo-1. 293 Cells were incubated for 24 h with irrelevant mouse IgM (a and b) or with two different mouse IgM mAbs specific for human Fas/Apo-1 (mAb 7C11, c and d; and mAb CH11, e and f, respectively) at a concentration of 2 g/ml (a, c and e) or 4 g/ml (b, d and f). The percentage of apoptotic cells is indicated between bars.
24 h after transfection with pBCMGSNeo FasL, and 59 ± 2.32% after transfection with pAL119-FasL; in comparison to 7.3 ± 1% of apoptosis detected in cells transfected with the empty plasmid, or 6 ± 2% in mock-transfected cells. After 48 h, the levels of apoptosis increased to 79 ± 7% in pBCMGSNeo-FasL transfected cells and to 66 ± 4.4% in pAL119 FasL transfected ones (Figure 4) . The apoptosis of 293 cells 48 h after transfection with pBCMGS Neo FasL or pAL119-FasL was also confirmed by DNA extraction gel electrophoresis. Figure 5 shows a high molecular weight smear of DNA extracted from FasL-transfected cells; this DNA degradation pattern has been previously described for apoptotic epithelial cells. 24 The original observation that certain immunologically privileged tissues, such as the testis and the anterior chamber of the eye, express FasL, led to the concept that the targeted ectopic expression of transgenic FasL could play an important role in suppressing the immune response against allogeneic transplants, or prolonging the expression from RAd, two experimental paradigms known to be limited by the development of inflammatory and adaptive immune responses. Thus, the construction of RAd-expressing FasL rests on solid theoretical ground. Two recent reports described the generation of recombinant vaccinia and baculovirus vectors encoding human or mouse FasL, which were produced on cells that are not sensitive to murine or human FasL-induced apoptosis. 25, 26 Our failure to produce a RAd-expressing FasL might be explained by apoptosis induced by our plasmid containing FasL under a very strong promoter, by the high level of Fas/Apo-1 molecule expressed in our 293 cells, or by both factors. To test the second hypothesis, we analysed the level of expression of membrane Fas/Apo-1 on 293 cells which had been used successfully by another group to generate a RAd encoding for FasL (cell line kindly provided by Dr I Anegon, INSERM U437, Nantes, France). Interestingly, we found that Fas/Apo-1 was only expressed at a level detected by flow cytometry by 30-40% of the total 293 cell population provided by Dr Anegon (data not shown), in comparison with 95-99% of positive cells detected in our 293 cells. Moreover, 24 h after transfection with pBCMGSNeo-FasL or pAL119-FasL the percentage of apoptosis in the 293 cells provided by Dr Anegon was lower (30 and 20%, respectively; data not shown) than in the 293 cells that we used in the present study (69 and 59%, respectively).
In this regard, in a recent work, a RAd encoding for
Figure 3 Apoptosis of 293 cells triggered by mouse Fas-L. 293 Cells 24 h after transfection with empty plasmid pBCMGS Neo (a) or with pBCMGS Neo-FasL (b) and (c) (a and b, ×100; c, ×200). Following transfection with pBCMGS Neo-FasL cells are smaller, and are detached from the plastic surface (b and c). (c) Cell nuclei show fragmentation (white arrowhead, scale bar, 10 m). Insert displays at higher magnification a cell with fragmented nucleus and condensed chromatin (×1000).
mouse FasL under the CMV-IE promoter has been generated, and was used to infect murine pancreatic islets before transplantation. 18 Although the authors report the successful production of a recombinant virus, they describe that infection of 293 cells with the RAd-encoding murine FasL results in rapid cell death and, as a consequence, a relatively lower titre of RAd, when compared with other vectors encoding non-toxic genes. Thus, the capacity to produce recombinant vaccinia and baculovirus vectors expressing FasL is most easily explained by the resistance of the virus producing cells to FasLinduced apoptosis; the success of Muruve et al and Zhang et al in producing a RAd could have been due to the use of a less powerful human cytomegalovirus (hCMV) promoter. 18, 27 It is known that different sequences from the hCMV promoter/enhancer can lead to important differences in transgene expression; the promoter used in our studies (−299 to +69) was selected because it affords very high expression levels due to the removal of most negative upstream regulatory sequences. 20 In the present study, we have demonstrated that 293 cells express functional Fas/Apo-1 and undergo apoptosis triggered either by agonist monoclonal antibodies, or by endogenous FasL expression induced after transfection with expression plasmids. Our results explain why 293 cells died during generation or scaling up of recombinant adenovirus encoding for FasL leading to a low titre of recombinant virus, or the impossibility of generating such recombinants at all.
293 Cells are normally used to generate RAd vectors since they constitute a transformed cell line derived from human embryonic kidney cells, that has a stable insertion comprising the left 11% of the adenoviral DNA. This region includes the E1a gene product which provides transcomplementation for replication-defective E1-deleted adenoviral vectors. 28 Despite the generation of some newer cell lines (eg 911 cell line) which incorporate better defined regions of the adenoviral genome, 293 cells are the most frequently transcomplementing or packaging cell line used to grow and isolate RAd. 29 Different approaches could circumvent FasL-induced apoptosis of 293 cells and the resulting low titre or absence of recombinant virus: (1) to silence the expression of FasL during the development of the viral vectors in 293 cells; (2) to incubate 293 cells either with inhibitors of FasL-induced apoptosis (eg caspase inhibitors or with anti-Fas antibodies which lack the capacity to induce apoptosis but hinder FasL-Fas/Apo-1 interactions); or (3) to grow the virus on a novel cell line not expressing Fas/Apo-1 which is stably transfected with adenovirus E1 region. 23, 30 A reduction or elimination of FasL expression during the generation of RAd could be achieved by placing the expression of FasL under the control of cell type-specific or -inducible promoter elements that reduce or delay expression of FasL enough to allow the generation of RAd. Any of these options should allow for a more efficient production and purification of RAd-expressing FasL. 1 and 2,  respectively) . DNA extraction and analysis were performed as previously described with slight modifications. 29 present work, and Tricia Maleniak and Ros Poulton for excellent technical and secretarial assistance, respectively.
